5 replies to this topic

[Michael Lustgarten]

Attached Files

•  ba7 thumb.png   508.78KB   0 downloads

[Michael Lustgarten]

 

Cardiovascular Disease Biomarker Deep Dive (Test #7 In 2025)

 

 

Attached Files

•  ba7 in 25 cvd biomark thumb.png   686.82KB   0 downloads

[Michael Lustgarten]

Part III: S-adenosyl-methionine: A Key Player For Lowering Homocysteine?

 

Attached Files

•  ba7 supps in 2025 thumb.png   371.44KB   0 downloads

[albedo]

As usual Michael, great video.

 

Give the variability of LP(a) (do you quantify that too?) how you can disentangle what is statistics from possible effects *caused* by external factors you act upon (diet, exercise, etc ...). I know LP(a) is largely genetics though but you also made a point in trying to get to low ASCVD % risk (great chart, btw). Very good you recommend to track data and not limit to one point.

 

BTW I decided (sorry ;-)) to go on low dose statins. 5-10 mg rosuvastatin dramatically improved all lipids biomarkers (unless LP(a) as i expected though). Still checking as I started recently about 70 yo. Very happy with numbers so far.

 

Also, as you are correlating to hsCRP I am running around 0.8 at 70 yo and also checking form time to time IL-6 and TNF-alpha.

 

Please keep up the good work!

[albedo]

sorry .. I forgot a piece of text: "....trying to get to low ASCVD % risk (great chart, btw) also by looking at hsCRP and lower inflammation". My apologizes.

[Michael Lustgarten]

Thanks albedo, will do, for as long as I live!

In terms of Lp(a) (or other biomarker variability), one way to account for it is by testing multiple times per year, and looking at year-to-year averages. Lp(a) is thought to be a relative constant, which has led many to say to only measure it once, but in my case, I've had values that have ranged from 70 to 145 nmol/L

Then, what's the recipe for keeping it low, not high? I've had some success with that, as the 10yr average is around 90 nmol/L (still too high, but not 145 nmol/L)

No worries on using a statin-note that statins don't generally reduce Lp(a), so I'd keep my eye on emerging meds that can lower it, especially when considering that Lp(a) is 6-7x more atherogenic than LDL...